Adastra Holdings Ltd. (formerly Phyto Extractions Inc.) (CSE: XTRX) (Frankfurt: D2EP) (“Adastra” or the “Company”), a leader in innovative ethnobotanical and cannabis science products, today announced the development of CBD isolate. The composition of CBD isolate enables recreational, medical and cosmetic products to be developed and marketed.
Specifically designed for patients and consumers seeking the benefits of CBD, but in a THC-free experience, this 99% pure crystalline CBD isolate is almost THC-free, eliminating the psychoactive effects. CBD isolate is available in a crystalline powder and can be formulated into a variety of products including tinctures, oils, topicals, vapes, and capsules.
“Substantial research clearly shows that CBD can reduce pain, anxiety and inflammation while protecting the skin,” said Jean-Paul Lim MD, FRCPC, Medical Director at PerceiveMD, a wholly owned subsidiary of Adastra operating in August 2021 . “In addition, CBD is very well tolerated, does not create euphoria and has a low risk of side effects. Hence, the isolate products we have developed are expected to provide the significant benefits of CBD without the psychoactive effects and to address significant and growing patient needs. In addition, CBD from hemp enables people who cannot tolerate THC due to sensitivities or who have certain psychological problems such as bipolar, schizophrenia, severe depression or anxiety to enjoy the benefits of CBD. ”
Added Donald Dinsmore , Adastra’s Chief Operating Officer, “Adastra has developed cryo-ethanol extraction processes that are extremely scalable for the extraction of cannabinoids from hemp and that enable compound isolation. CBD isolate is an attractive ingredient for a variety of medical and recreational products – it is very pure with more than 99% CBD and can be obtained from hemp, a very inexpensive raw material. With the successful development of a CBD isolate, we are now developing a range of medicinal and consumer-oriented products. These products take advantage of our recent acquisition of PerceiveMD. Once we have obtained a medical distribution license, which is expected before the end of the year, we will prescribe medical and related products through PerceiveMD patient centers and other channels.
Adastra plans to distribute its CBD isolation products through multiple channels. With the recently completed acquisition of PerceiveMD, Adastra has access to over 4,500 patients searching for holistic medicines. In addition, Adastra will have immediate distribution through the Ageless Living clinics in British Columbia and Alberta and third-party clinics everywhere Canada .
About Adastra Holdings Ltd.
Adastra was founded in 2018 and was formerly known as Phyto Extractions Inc. Adastra is a leading manufacturer and supplier of innovative ethnobotanical and cannabis science products designed for the adult, medical and future therapeutic applications. Adastra is known everywhere Canada for its popular line of Phyto Extractions brand cannabis concentrate products on the shelves of over 1,400 adult retailers across the country. The company also operates Adastra Labs, a 13,500 square foot farm-scale facility licensed by Health Canada Langley, BC ., focuses on the extraction, distillation and manufacture of cannabis products. Adastra has now successfully taken the first steps to become a licensed breeder, tester, extractor and seller of controlled substances including psilocybin, psilocin, MDMA, N, N-dimethyltryptamine (DMT), 5-MeO-DMT and LSD through the Application for a Controlled Substance Dealer License, which is reviewed by Health Canada. Pending approval by Health Canada, Adastra stands ready to be a leader in drug formulation and development in this emerging sector. In addition, with the recent takeover of 1225140 B .C. Ltd., operating as PerceiveMD, Adastra operates a multidisciplinary center for medical cannabis and psychedelic therapies and works with doctors and health care professionals within the regulated environment to develop effective remedies that meet the real needs of patients.
Connect to Adastra: Email | Website | Instagram | LinkedIn | Twitter | Facebook
ON BEHALF OF THE MANAGEMENT BOARD
Adastra Holdings LTD. (CSE: XTRX)
Forward-looking information:
This press release contains forward-looking information within the meaning of Canadian securities laws relating to the company’s business. Forward-looking information is based on certain key expectations and assumptions made by the company’s management. While the company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should be placed on forward-looking information as the company cannot guarantee that it will prove to be accurate. Forward-looking information in this press release includes statements relating to the distributor license for controlled drugs and substances; the changing regulations regarding certain psychedelics and related treatments; social acceptance of psychedelic treatments; the company’s ability to test, manufacture, or sell compounds beyond cannabis; and the company’s ability to work with partners such as doctors, drug companies, and pharmacies when allowed to conduct extraction research and develop psychedelic compounds. There are numerous risks and uncertainties that could cause actual results and the company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks inherent in the cannabis extraction sector in general; (iii) changes in regulations on several controlled substances; and (iv) other factors beyond the control of the company. Actual results and future events could differ materially from those anticipated in this information. This and all subsequent written and oral forward-looking information are based on the estimates and opinions of management at the time of their publication and are expressly restricted in their entirety by this release. Unless required by law, the company does not intend to update these forward-looking statements.
The Canadian Securities Exchange has not reviewed or approved the contents of this press release.
View original content to download multimedia: https://www.prnewswire.com/news-releases/adastra-holdings-enters-market-with-creation-of-thc-free-99-pure-cbd-isolate-301387792.html
SOURCE Adastra Holdings Ltd.
source https://www.bisayanews.com/2021/09/29/adastra-holdings-enters-market-with-creation-of-thc-free-99-pure-cbd-isolate/
No comments:
Post a Comment